BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™️ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A

BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™️ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A
Image

Please enable the javascript to submit this form

Supported through educational grants from BioMarin, CSL Behring, Pfizer Inc., and Spark Therapeutics

Essential SSL